These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 6484838)

  • 1. [Treatment of hyperphosphatemia in chronic renal failure].
    Babarykin DA; Afanas'eva GA; Shul'man OM; Luse LIa; Rozental' RL
    Ter Arkh; 1984; 56(7):64-6. PubMed ID: 6484838
    [No Abstract]   [Full Text] [Related]  

  • 2. [Methods of correcting hyperphosphatemia in chronic renal failure and in dialysis (review)].
    Novikov AI
    Ter Arkh; 1997; 69(12):63-7. PubMed ID: 9503540
    [No Abstract]   [Full Text] [Related]  

  • 3. Calcium carbonate in hyperphosphatemia.
    Mayo M; Middleton RK
    DICP; 1991 Sep; 25(9):945-7. PubMed ID: 1949973
    [No Abstract]   [Full Text] [Related]  

  • 4. Phosphate binders in hyperphosphatemia of chronic renal failure.
    Wasan SM; Godley PJ
    DICP; 1991 Sep; 25(9):942-5. PubMed ID: 1949972
    [No Abstract]   [Full Text] [Related]  

  • 5. The clinical management of hyperphosphatemia.
    Ritz E
    J Nephrol; 2005; 18(3):221-8. PubMed ID: 16013007
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and side-effect profile of sevelamer hydrochloride used in combination with conventional phosphate binders.
    Sturtevant JM; Hawley CM; Reiger K; Johnson DW; Campbell SB; Burke JR; Bofinger A; Isbel NM
    Nephrology (Carlton); 2004 Dec; 9(6):406-13. PubMed ID: 15663645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Calcium carbonate as an alternative to aluminium hydroxide in maintenance haemodialysis for chronic renal failure.
    O'Brien A; McParland C; Keogh B
    Ir Med J; 1987 Feb; 80(2):68-70. PubMed ID: 3557928
    [No Abstract]   [Full Text] [Related]  

  • 8. Aluminum hydroxide, calcium carbonate and calcium acetate in chronic intermittent hemodialysis patients.
    Janssen MJ; van der Kuy A; ter Wee PM; van Boven WP
    Clin Nephrol; 1996 Feb; 45(2):111-9. PubMed ID: 8846523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of high CaCO3 supplements on serum calcium and phosphorus in patients on regular hemodialysis treatment.
    Gonella M; Calabrese G; Vagelli G; Pratesi G; Lamon S; Talarico S
    Clin Nephrol; 1985 Sep; 24(3):147-50. PubMed ID: 4042444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Calcium carbonate, an aluminum-free agent for control of hyperphosphatemia, hypocalcemia, and hyperparathyroidism in uremia.
    Fournier A; Moriniere P; Sebert JL; Dkhissi H; Atik A; Leflon P; Renaud H; Gueris J; Gregoire I; Idrissi A
    Kidney Int Suppl; 1986 Feb; 18():S114-9. PubMed ID: 3457987
    [No Abstract]   [Full Text] [Related]  

  • 11. Substitution of aluminium hydroxide by high doses of calcium carbonate in patients on chronic haemodialysis: disappearance of hyperaluminaemia and equal control of hyperparathyroidism.
    Moriniere P; Roussel A; Tahiri Y; de Fremont JF; Maurel G; Jaudon MC; Gueris J; Fournier A
    Proc Eur Dial Transplant Assoc; 1983; 19():784-7. PubMed ID: 6878265
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Aluminum hydroxide treatment of hyperphosphatemia in uremia].
    Bergquist-Poppen M; Bergström J; Wallin R
    Lakartidningen; 1972 May; 69(19):2319-20. PubMed ID: 5035811
    [No Abstract]   [Full Text] [Related]  

  • 13. Is there increasing evidence to change the management of renal bone disease?
    Harum P
    Nephrol News Issues; 1999 Apr; 13(4):55-6. PubMed ID: 10418451
    [No Abstract]   [Full Text] [Related]  

  • 14. [Acute hyperphosphatemia secondary to phosphate administration for bowel preparation].
    Gutiérrez E; González E; Hernández E; Herrero JC; Manzanera MJ; García JA; Domínguez-Gil B; Praga M
    Nefrologia; 2004; 24(3):283-7. PubMed ID: 15283320
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Administration of colloidal aluminium hydroxide to patients under chronic hemodialysis].
    Vokrouhlická O; Erben J; Zahradník J; Dvoráková-Bastecká D
    Cas Lek Cesk; 1977 May; 116(19):594-7. PubMed ID: 880597
    [No Abstract]   [Full Text] [Related]  

  • 16. [Features of correction of phosphate-calcium metabolism disorders in terminal renal failure].
    Pilotovich VS; Romanovich VP; Shilaĭ LM; Tukaĭ NN
    Klin Med (Mosk); 1992; 70(3-4):49-51. PubMed ID: 1507848
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of oral administration of calcium carbonate, aluminum hydroxide gel and dihydrotachysterol on renal acidosis.
    Ueda H; Ikeda H; Sasaki Y; Shioji R
    Tohoku J Exp Med; 1978 Jan; 124(1):1-11. PubMed ID: 635890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Value of large doses of calcium carbonate for the control of serum level of phosphorus in children with terminal renal failure].
    Sieniawska M; Rośzkowska-Blaim M; Krzemień G; Fijałkowska A; Makarewicz W; Lewicki Z
    Pol Tyg Lek; 1988 Apr; 43(15):475-7. PubMed ID: 3405879
    [No Abstract]   [Full Text] [Related]  

  • 19. The treatment of uremic hyperphosphatemia.
    Schaefer K
    Clin Nephrol; 1996 Oct; 46(4):279-80. PubMed ID: 8905221
    [No Abstract]   [Full Text] [Related]  

  • 20. Calcium carbonate can enhance aluminium absorption from aluminium hydroxide in patients with impaired renal function.
    Lin JL; Leu ML
    Nephrol Dial Transplant; 1996 Sep; 11(9):1891-3. PubMed ID: 8918652
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.